Clinical Trials Browser

Phase 3 × Withdrawn × rovalpituzumab tesirine × Clear all

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 3 Withdrawn

Neoplasms, Small Cell Lung Carcinoma